{"id":"tace-with-drug-eluting-beads-procedure","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Post-embolization syndrome (fever, abdominal pain, nausea)"},{"rate":"30-50","effect":"Hepatic dysfunction/elevated liver enzymes"},{"rate":"20-40","effect":"Fatigue"},{"rate":"10-30","effect":"Vomiting"},{"rate":"1-5","effect":"Arterial dissection or perforation"},{"rate":"1-3","effect":"Hepatic abscess"}]},"_chembl":{"chemblId":"CHEMBL5798639","moleculeType":null,"molecularWeight":"399.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a minimally invasive interventional procedure that combines transarterial chemoembolization (TACE) with drug-eluting beads (DEBs) that are loaded with chemotherapeutic agents. The beads are injected into the hepatic artery feeding the tumor, where they lodge in the tumor vasculature, releasing chemotherapy locally while simultaneously occluding blood flow to starve the tumor of oxygen and nutrients.","oneSentence":"TACE with drug-eluting beads delivers chemotherapy directly to hepatocellular carcinoma tumors via arterial catheterization while blocking blood supply to the tumor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:10:44.457Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), unresectable or as bridge to transplantation"}]},"trialDetails":[{"nctId":"NCT03753659","phase":"PHASE2","title":"IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2019-05-09","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":30},{"nctId":"NCT07449065","phase":"","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI)","enrollment":324},{"nctId":"NCT07322848","phase":"PHASE3","title":"DEB-TACE vs cTACE in HCC After TIPS","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-12-01","conditions":"Hepatocellular Carcinoma (HCC), TACE, TIPS","enrollment":206},{"nctId":"NCT03638141","phase":"PHASE2","title":"CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-10-02","conditions":"Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma","enrollment":21},{"nctId":"NCT03143270","phase":"EARLY_PHASE1","title":"A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-04-28","conditions":"Liver Cancer","enrollment":20},{"nctId":"NCT03045497","phase":"PHASE1","title":"Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-12-12","conditions":"Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT06555003","phase":"PHASE3","title":"DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases","status":"RECRUITING","sponsor":"Tehran University of Medical Sciences","startDate":"2025-01-20","conditions":"Liver Neoplasm, Colorectal Cancer Metastatic","enrollment":116},{"nctId":"NCT04803994","phase":"PHASE3","title":"The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2021-07-06","conditions":"Hepatocellular Carcinoma","enrollment":434},{"nctId":"NCT06353126","phase":"PHASE4","title":"DEB-TACE Prior to Liver Transplantation in the Treatment of HCC","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-10-16","conditions":"Liver Cancer","enrollment":40},{"nctId":"NCT03960008","phase":"PHASE3","title":"Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant","status":"TERMINATED","sponsor":"Lahey Clinic","startDate":"2020-03-01","conditions":"Hepatocellular Carcinoma, HCC","enrollment":9},{"nctId":"NCT02182687","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant","status":"COMPLETED","sponsor":"Lahey Clinic","startDate":"2014-06","conditions":"Hepatocellular Carcinoma, HCC","enrollment":60},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT05862181","phase":"","title":"The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-01-01","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":200},{"nctId":"NCT05794971","phase":"PHASE3","title":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-06-10","conditions":"Colorectal Cancer Liver Metastases, Regorafenib","enrollment":126},{"nctId":"NCT04967482","phase":"NA","title":"DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2021-07-09","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":216},{"nctId":"NCT04174781","phase":"PHASE2","title":"Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2019-11-20","conditions":"Hepatocellular Carcinoma","enrollment":61},{"nctId":"NCT02794337","phase":"PHASE2, PHASE3","title":"TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer","status":"UNKNOWN","sponsor":"Tata Memorial Hospital","startDate":"2014-12","conditions":"Carcinoma, Hepatocellular","enrollment":67},{"nctId":"NCT04780789","phase":"","title":"Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization","status":"COMPLETED","sponsor":"Brno University Hospital","startDate":"2015-02-01","conditions":"Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage","enrollment":61},{"nctId":"NCT03007225","phase":"PHASE4","title":"Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2015-07","conditions":"HepatoCellular Carcinoma","enrollment":50},{"nctId":"NCT01891539","phase":"","title":"Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"International Group of Endovascular Oncology","startDate":"2013-05","conditions":"Liver Cell Carcinoma Non-resectable","enrollment":100},{"nctId":"NCT00293397","phase":"NA","title":"Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-11","conditions":"Liver Cancer","enrollment":20},{"nctId":"NCT02729506","phase":"PHASE4","title":"Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2016-01","conditions":"Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT00877071","phase":"PHASE2","title":"LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2008-11","conditions":"Hepatocellular Carcinoma","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":78,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DEB-TACE"],"phase":"marketed","status":"active","brandName":"TACE with Drug Eluting Beads procedure","genericName":"TACE with Drug Eluting Beads procedure","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TACE with drug-eluting beads delivers chemotherapy directly to hepatocellular carcinoma tumors via arterial catheterization while blocking blood supply to the tumor. Used for Hepatocellular carcinoma (HCC), unresectable or as bridge to transplantation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}